Johnson & Johnson (NYSE: JNJ) expanded the rollout of its latest Tecnis Odyssey presbyopia-correcting intraocular lenses ...

The Alcon Innovator Program aimed to gain patient insights from across the country to understand the most common areas of ...

with one out of two ATIOLs being an Alcon product. The company’s flagship lenses, Vivity and PanOptix, continue to lead the category in the United States and around the world. Additionally ...

This includes the novel 1-week contact lens Precision-7, the next version of PanOptix, and the potential FDA approval of AR-15512 for dry eye treatment. Alcon’s management expects these new ...

Cooper’s pricing power and cost optimization efforts are expected to drive margin expansion. Read why I reiterate a Buy ...

Alcon Inc. ALC benefits from strong market ... banking on advanced technology intraocular lenses that includes Vivity, PanOptix and monofocaltorics. In Consumables, sales continue to grow, driven ...

Surgical Business Grows: Alcon’s Surgical business continues to gain from the company’s diverse portfolio and incremental innovation. ALC’s flagship lenses, Vivity and PanOptix, continue to ...

5. Next-generation PanOptix: The introduction of an improved version of this popular IOL is expected to drive growth in the cataract segment. 6. New contact lens modality: Alcon plans to introduce ...

Let’s delve deeper. Surgical Business Grows: Alcon’s Surgical business continues to gain from the company’s diverse portfolio and incremental innovation. ALC’s flagship lenses, Vivity and PanOptix, ...